84 related articles for article (PubMed ID: 29263494)
21. Receptors for advanced glycation end products (RAGE) is associated with microvessel density and is a prognostic biomarker for clear cell renal cell carcinoma.
Guo Y; Xia P; Zheng JJ; Sun XB; Pan XD; Zhang X; Wu CZ
Biomed Pharmacother; 2015 Jul; 73():147-53. PubMed ID: 26211596
[TBL] [Abstract][Full Text] [Related]
22. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
[TBL] [Abstract][Full Text] [Related]
23. HCRP-1 regulates cell migration and invasion via EGFR-ERK mediated up-regulation of MMP-2 with prognostic significance in human renal cell carcinoma.
Chen F; Deng J; Liu X; Li W; Zheng J
Sci Rep; 2015 Aug; 5():13470. PubMed ID: 26304749
[TBL] [Abstract][Full Text] [Related]
24. A1CF-promoted colony formation and proliferation of RCC depends on DKK1-MEK/ERK signal axis.
Ni D; Yi Q; Liu J; Hu Y; Lv T; Tan G; Liu Y; Xu L; Xia H; Zhou Q; Xie Y
Gene; 2020 Mar; 730():144299. PubMed ID: 31881249
[TBL] [Abstract][Full Text] [Related]
25. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.
Gassenmaier M; Chen D; Buchner A; Henkel L; Schiemann M; Mack B; Schendel DJ; Zimmermann W; Pohla H
Stem Cells; 2013 Aug; 31(8):1467-76. PubMed ID: 23630186
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM
Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320
[TBL] [Abstract][Full Text] [Related]
27. Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
Nakai Y; Miyake M; Morizawa Y; Hori S; Tatsumi Y; Anai S; Onishi S; Tanaka N; Fujimoto K
Oncol Rep; 2017 Jan; 37(1):227-234. PubMed ID: 27840968
[TBL] [Abstract][Full Text] [Related]
28. Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice.
Karashima T; Inoue K; Fukata S; Iiyama T; Kurabayashi A; Kawada C; Shuin T
Int J Oncol; 2007 Apr; 30(4):937-45. PubMed ID: 17332933
[TBL] [Abstract][Full Text] [Related]
29. Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways.
Gobe GC; Ng KL; Small DM; Vesey DA; Johnson DW; Samaratunga H; Oliver K; Wood S; Barclay JL; Rajandram R; Li L; Morais C
Biochem Biophys Res Commun; 2016 Apr; 473(1):47-53. PubMed ID: 26995091
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
32. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
Heard JJ; Phung I; Potes MI; Tamanoi F
BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
[TBL] [Abstract][Full Text] [Related]
33. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma.
Rivet J; Mourah S; Murata H; Mounier N; Pisonero H; Mongiat-Artus P; Teillac P; Calvo F; Janin A; Dosquet C
Cancer; 2008 Jan; 112(2):433-42. PubMed ID: 18041056
[TBL] [Abstract][Full Text] [Related]
34. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of hTERT expression by MAP kinase inhibitor induces cell death in renal cell carcinoma.
Pal D; Sharma U; Singh SK; Kakkar N; Prasad R
Urol Oncol; 2017 Jun; 35(6):401-408. PubMed ID: 28215740
[TBL] [Abstract][Full Text] [Related]
37. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
38. Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models.
Gao H; Jiang Q; Han Y; Peng J; Wang C
Cell Biochem Biophys; 2015 Mar; 71(2):757-64. PubMed ID: 25260394
[TBL] [Abstract][Full Text] [Related]
39. [Expression of VEGFR-2 and VEGFR-3 in papillary renal cell carcinoma and their relationship with prognosis].
Zhang YH; Diao L; Yang Q; Duo J; Liu YX; Liu SX; Yao X
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):752-6. PubMed ID: 21163065
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
